Medikamentöse Behandlung des NSCLC Stadium IIIB/IV: Aktuelle Fortschritte durch Therapieindividualisierung

ISSN： 0945-5566

Source： PZ PRISMA, Vol.19, Iss.4, 2012-10, pp. : 211-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Medizin Künstliches Hypericin zur Behandlung des CTCL

By Zündorf Ilse Fürst Robert Dingermann Theo

PHARMAKON, Vol. 4, Iss. 1, 2016-01 ,pp. : 4-4

Govi-Verlag

Access to resources Recommend Favorite

Basiliximab: A Viewpoint by Björn Nashan

By Nashan B.

Drugs, Vol. 57, Iss. 2, 1999-02 ,pp. : 214-214

Adis International

Access to resources Recommend Favorite

Memantine: A Viewpoint by Hans Förstl

By Förstl H.

Drugs & Aging, Vol. 20, Iss. 6, 2003-01 ,pp. : 477-478

Adis International

Access to resources Recommend Favorite

Carboplatin combined with an alternating regimen of IV and oral vinorelbine is effective and well tolerated in patients with NSCLC,

Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Sjögren's Syndrome: Diagnosis and Therapeutic Challenges in the Elderly

By Ng Kristine P. Isenberg David A.

Drugs & Aging, Vol. 25, Iss. 1, 2008-01 ,pp. : 19-33

Adis International

Access to resources Recommend Favorite